Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 173

Sort by

Sort Order Select

Journal Articles

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Blood (2024) 144 (15): 1570–1580.

https://doi.org/10.1182/blood.2023023754

Published: 2024

Includes: Supplemental data

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

The stepbrothers of ABLSON have their own sensitivity

Philippe Rousselot

Blood (2024) 143 (21): 2117–2118.

https://doi.org/10.1182/blood.2024024121

Published: 2024

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Old rivals become new friends

Philippe Rousselot

Blood (2024) 143 (5): 380–382.

https://doi.org/10.1182/blood.2023022822

Published: 2024

Journal Articles

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Blood (2023) 142 (Supplement 1): 844.

https://doi.org/10.1182/blood-2023-179298

Published: 2023

Journal Articles

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Blood (2023) 142 (Supplement 1): 518.

https://doi.org/10.1182/blood-2023-179192

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Blood (2023) 142 (Supplement 1): 78.

https://doi.org/10.1182/blood-2023-181250

Published: 2023

Journal Articles

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2023) 142 (Supplement 1): 3164.

https://doi.org/10.1182/blood-2023-178790

Published: 2023

Journal Articles

Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study

Blood (2023) 142 (Supplement 1): 962.

https://doi.org/10.1182/blood-2023-177696

Published: 2023

Journal Articles

IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

Lucien Courtois, Aurélie Cabannes-Hamy, Rathana Kim, Marine Delecourt, Antoine Pinton, Guillaume Charbonnier, Mélanie Feroul, Charlotte Smith, Giulia Tueur, Cécile Pivert, Estelle Balducci, Mathieu Simonin, Laure Hélène Angel, Salvatore Spicuglia, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi, Philippe Rousselot, Ludovic Lhermitte

Blood (2023) 142 (2): 158–171.

https://doi.org/10.1182/blood.2022017948

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Blood (2023) 141 (11): 1353–1358.

https://doi.org/10.1182/blood.2022017755

Published: 2023

Includes: Supplemental data

Journal Articles

Metabolic Plasticity Reveals a Targetable Vulnerability in Leukemia

Guillaume P Andrieu, Mathieu Simonin, Aurélie Cabannes-Hamy, Etienne Lengline, Ambroise Marçais, Marie Emilie Dourthe, Nicolas Boissel, Hervé Dombret, Philippe Rousselot, Olivier Hermine, Vahid Asnafi

Blood (2022) 140 (Supplement 1): 5893–5895.

https://doi.org/10.1182/blood-2022-168665

Published: 2022

Journal Articles

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Blood (2022) 140 (Supplement 1): 6760–6762.

https://doi.org/10.1182/blood-2022-157956

Published: 2022

Journal Articles

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Blood (2022) 140 (Supplement 1): 1495–1497.

https://doi.org/10.1182/blood-2022-157822

Published: 2022

Journal Articles

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Rathana KIM, Marc Delord, Michael Doubek, Francoise Huguet, Aurelie Cabannes-Hamy, Ulla Wartiovaara-Kautto, Colombe Saillard, Emmanuel Raffoux, Thomas Cluzeau, Stephane Lepretre, Marie Balsat, Anna Berceanu, Nicolas Boissel, Claude Gardin, Emmanuelle Clappier, Herve Dombret, Philippe Rousselot

Blood (2022) 140 (Supplement 1): 6114–6116.

https://doi.org/10.1182/blood-2022-166035

Published: 2022

Journal Articles

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Blood (2022) 140 (Supplement 1): 112–114.

https://doi.org/10.1182/blood-2022-157903

Published: 2022

NARROW

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

The stepbrothers of ABLSON have their own sensitivity

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Old rivals become new friends

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Involvement of the JAK-STAT Pathway in the Molecular Landscape of Fusion-Free Myeloid Neoplasms with Eosinophilia

Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study

IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Metabolic Plasticity Reveals a Targetable Vulnerability in Leukemia

Molecular Response of ≤10% BCR::ABL1 IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only